Across TCGA pan-cancer cohorts, ARHGEF12 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ARHGEF12 data layer compared with 23 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher ARHGEF12 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated ARHGEF12 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and GBM show a favorable association.

CCRCC, GBM, and PDAC are the cancer types where ARHGEF12 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	III,IV	0.872	0.386	<.001	69	view →
GBM	OS	Median	All	0.550	0.275	.003	18	view →
PDAC	OS	Tertile	All	0.938	0.785	.004	18	view →
HNSC	DFS	Quartile	III,IV	0.883	0.589	.020	9	view →
LUAD	DFS	Quartile	All	1.000	0.768	.035	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: ARHGEF12 tumor-vs-normal RNA expression · all ARHGEF12 data types